Literature DB >> 22350695

Short-term reductions in non-protein respiratory quotient and prealbumin can be associated with the long-term deterioration of liver function after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.

Masaya Saito1, Yasushi Seo, Yoshihiko Yano, Akira Miki, Masaru Yoshida, Takeshi Azuma.   

Abstract

BACKGROUND: Transcatheter arterial chemoembolization (TACE) is an effective treatment for hepatocellular carcinoma (HCC) that can cause deterioration of liver function. We aimed to make an early predictive model of long-term liver dysfunction after TACE.
METHODS: We performed a prospective cohort study involving 109 HCC patients who underwent TACE at Kobe University Hospital. Indirect calorimetry and blood biochemical examinations were performed before and 7 days after TACE. As an indicator of liver function, the Child's score was evaluated before and 3 months after TACE. Patients with and without Child's score deterioration were compared, and the independent risk factors for Child's score deterioration were statistically examined. An early predictive model of Child's score deterioration after TACE was developed using multivariate logistic regression.
RESULTS: Multivariate analyses showed that the non-protein respiratory quotient (npRQ) and prealbumin (preAlb) ratios (7 days after/before TACE) were independent determinants of Child's score deterioration (p = 0.039 and 0.020, respectively). Decreases of the npRQ and preAlb ratios were significantly related to increases of Child's score 3 months after TACE (p = 0.007 and 0.002, respectively). The following predictive model of Child's score deterioration was developed: exp(-6.383 × npRQ ratio - 3.038 × preAlb ratio + 7.755)/(1 + exp(-6.383 × npRQ ratio - 3.038 × preAlb ratio + 7.755)). The model discriminated well between patients with and without Child's score deterioration (area under the receiver operating curve [ROC]; AUC 0.713; 95% confidence interval [CI] 0.613-0.812). The optimal cut-off point for the Child's score was 0.449, and the sensitivity and specificity of the model were 57.1 and 79.1%, respectively.
CONCLUSIONS: Reductions in npRQ and preAlb 7 days after TACE were associated with the long-term deterioration of liver function. With our model, we were able to identify high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350695     DOI: 10.1007/s00535-012-0535-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  36 in total

1.  Protein-calorie malnutrition in liver cirrhosis.

Authors:  H U Lautz; O Selberg; J Körber; M Bürger; M J Müller
Journal:  Clin Investig       Date:  1992-06

2.  Serum prealbumin: Is it a marker of nutritional status or of risk of malnutrition?

Authors:  Alan Shenkin
Journal:  Clin Chem       Date:  2006-12       Impact factor: 8.327

3.  The effect of a late evening snack in patients with liver cirrhosis.

Authors:  Masako Tsuchiya; Isao Sakaida; Mariko Okamoto; Kiwamu Okita
Journal:  Hepatol Res       Date:  2005-01-06       Impact factor: 4.288

4.  Transcatheter arterial embolization in unresectable hepatocellular carcinoma.

Authors:  R Yamada; K Kishi; T Sonomura; M Tsuda; S Nomura; M Satoh
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

Review 5.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

Review 6.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

7.  Are patients with liver cirrhosis hypermetabolic?

Authors:  M J Müller; K H Böker; O Selberg
Journal:  Clin Nutr       Date:  1994-06       Impact factor: 7.324

8.  Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis.

Authors:  K Nielsen; J Kondrup; L Martinsen; B Stilling; B Wikman
Journal:  Br J Nutr       Date:  1993-05       Impact factor: 3.718

9.  Hyperglucagonemia in hepatic cirrhosis: its relation to hepatocellular dysfunction and normalization on recovery.

Authors:  U M Kabadi; A B Eisenstein; J Tucci; J Pellicone
Journal:  Am J Gastroenterol       Date:  1984-02       Impact factor: 10.864

10.  Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.

Authors:  G Pelletier; M Ducreux; F Gay; M Luboinski; H Hagège; T Dao; W Van Steenbergen; C Buffet; P Rougier; M Adler; J P Pignon; A Roche
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

View more
  9 in total

1.  A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Masaru Yoshida; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2012-03-24       Impact factor: 7.527

2.  Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.

Authors:  Hiroki Nishikawa; Norihiro Nishijima; Hirayuki Enomoto; Azusa Sakamoto; Akihiro Nasu; Hideyuki Komekado; Takashi Nishimura; Ryuichi Kita; Toru Kimura; Hiroko Iijima; Shuhei Nishiguchi; Yukio Osaki
Journal:  Oncol Lett       Date:  2017-05-31       Impact factor: 2.967

3.  Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging: A potential utility for the evaluation of regional liver function impairment following transcatheter arterial chemoembolization.

Authors:  Yu-Dong Xiao; Ramchandra Paudel; Huan Liu; Bin Zhang; Cong Ma; Shun-Ke Zhou
Journal:  Oncol Lett       Date:  2014-12-23       Impact factor: 2.967

4.  Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Kyohei Kishino; Yoshihiro Shimono; Kunihiro Hasegawa; Chikage Nakano; Ryo Takata; Akio Ishii; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

5.  Liver function and energy metabolism in hepatocellular carcinoma developed in patients with hepatitis B-related cirrhosis.

Authors:  Meixin Ren; Juan Li; Ran Xue; Zhongying Wang; Shengli Li Coll; Qinghua Meng
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Kenji Momose; Hirotaka Hirano; Masaru Yoshida; Takeshi Azuma
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

7.  Alteration of non-protein respiratory quotient after hepatocellular carcinoma treatment can be related to des-γ-carboxy prothrombin before treatment.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Kenji Momose; Hirotaka Hirano; Masaru Yoshida; Takeshi Azuma
Journal:  Springerplus       Date:  2012-11-29

8.  The value of serum prealbumin in the diagnosis and therapeutic response of tuberculosis: a retrospective study.

Authors:  Hu Luo; Bingjing Zhu; Liang Gong; Jingxiang Yang; Yongyuan Jiang; Xiangdong Zhou
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

9.  Association between Albumin-Bilirubin Grade and Non-Protein Respiratory Quotient in Patients with Chronic Liver Diseases.

Authors:  Ryo Takata; Hiroki Nishikawa; Hirayuki Enomoto; Kazunori Yoh; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Kunihiro Hasegawa; Noriko Ishii; Yukihisa Yuri; Takashi Nishimura; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.